Monitor Q4 2026 for enrollment completion in ADVANCED-2 and interim THRIVE-3 data, which are the next major catalysts. The ADVANCED-3 redesign is a strategic shift that may delay a registrational path in BCG-Naive patients, increasing uncertainty around the NMIBC program's timeline.
Price Chart
Executive Summary
Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending on clinical trials. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $21.7 million, or $0.36 per share, compared to a net loss of $15.0 million, or $0.35 per share, in Q2 2025.
- Cash, cash equivalents and investments totaled $161.9 million as of June 30, 2026, expected to support operations into 2028.
- The ADVANCED-3 trial is being redesigned as a multi-cohort, open-label, exploratory trial to study TARA-002 in a broader NMIBC patient population.
- Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in Q4 2026.
- Interim results from the THRIVE-3 registrational trial of IV Choline Chloride are expected in Q4 2026.
- TARA-002 demonstrated clinical success in 83% (10/12) of participants that completed treatment in the STARBORN-1 trial for LMs.
Financial Impact
Net loss widened by $6.7M YoY to $21.7M in Q2 2026; R&D expenses increased by $6.2M to $17.0M.
Risk Factors
- Widening net losses with no near-term revenue prospects increase cash burn rate.
- Redesign of ADVANCED-3 trial introduces uncertainty in the NMIBC development timeline and regulatory path.
- Clinical trial enrollment and data readout risks across all pipeline programs (NMIBC, LMs, IV Choline Chloride).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-087506 |
| Document: ea0299236-8k_protara.htm | 0001213900-26-087506 |
| Document: 0001213900-26-087506-index-headers.html | 0001213900-26-087506 |
| Document: 0001213900-26-087506-index.html | 0001213900-26-087506 |
| Document: 0001213900-26-087506.txt | 0001213900-26-087506 |
| 8-K Data (Synthetic) | 0001213900-26-087506 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 Viewing No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers